NAMSA has extensive experience with cardiac, cardiovascular, and neurovascular devices and supports a myriad of these project types annually. Our technical specialists and scientists are adept at developing preclinical testing programs and evaluating the biocompatibility and functionality of such devices. Working in close collaboration with our specialists, NAMSA’s product development teams are well-versed and experienced in confronting global regulatory, reimbursement and commercialization challenges head-on to achieve accelerated cardiovascular device development outcomes.
Some of most common projects include: cardiovascular devices for hypertension; cardiac mapping technologies; coronary saphenous vein grafts (SVG); counterpulsation pump devices; heart failure devices; ICD and RCT therapies; left atrial appendage occlusion devices; left ventricular assist devices (adult and pediatric); orbital atherectomy systems; robotic ablation for atrial fibrillation; and therapeutic lead EP and intravascular ultrasound devices.
